Back to today’s briefing

Story perspectives

Harmony Biosciences Shares Plunge 16.6% After Trial Failure

9/25/2025

32 2

Summary

Story summary

Harmony Biosciences' shares fell 16.6% after ZYN002 failed in a Fragile X syndrome trial.
The trial enrolled 215 patients aged 3 to 29 and missed its primary endpoint, with a higher-than-expected placebo response contributing to the result.
Analyst Ami Fadia said the outcome was not surprising.
Harmony will analyze the full dataset to understand Fragile X syndrome.

1 of 1

Story summary

Harmony Biosciences' shares fell 16.6% after ZYN002 failed in a Fragile X syndrome trial.
The trial enrolled 215 patients aged 3 to 29 and missed its primary endpoint, with a higher-than-expected placebo response contributing to the result.
Analyst Ami Fadia said the outcome was not surprising.
Harmony will analyze the full dataset to understand Fragile X syndrome.